Rivian stock drops nearly 6% as CEO share-sale filing hits the tape in thin year-end trade

Rivian stock drops nearly 6% as CEO share-sale filing hits the tape in thin year-end trade

NEW YORK, December 30, 2025, 13:30 ET — Regular session

  • Rivian shares down about 6% in midday trade, lagging a muted broader market.
  • A Form 4 filed Monday showed CEO R.J. Scaringe sold 17,450 shares on Dec. 23 under a pre-arranged trading plan.
  • Investors are watching Fed minutes later Tuesday and Tesla’s delivery report on Friday for an EV-demand read-through.

Rivian Automotive, Inc shares were down about 6% on Tuesday, pulling back in a light year-end session after a regulatory filing disclosed a stock sale by Chief Executive Officer Robert J. Scaringe.

The move matters because thin holiday liquidity can exaggerate swings in high-volatility names, and investors have shifted back to demand signals and funding risk across electric-vehicle makers.

Traders also had one eye on U.S. Federal Reserve minutes due later in the session and a closely watched Tesla update on quarterly deliveries, events that can reset risk appetite for the sector.

A Form 4 filed on Monday showed Scaringe sold 17,450 Rivian shares on Dec. 23 at a weighted average price of $21.4253, in transactions that ranged from $21.21 to $21.69, and noted the sale was made under a Rule 10b5-1 plan — a pre-set trading arrangement that schedules sales in advance. SEC

Rivian was trading at $19.45 as of 1:30 p.m. ET, down $1.23 on the day. The stock has ranged from $20.78 to $19.30 in Tuesday’s session.

Rivian’s shares have been volatile in December after the company highlighted a push into self-driving technology and software, including an in-house autonomy processor and a paid driver-assistance package, which drew bullish commentary from some analysts at the time. Reuters

Sector sentiment has also been in play. Tesla’s fourth-quarter deliveries are expected to fall as the loss of U.S. tax credits and competition weigh on demand, and the company is due to report production and delivery numbers on Friday, a Reuters report said. Reuters

The broader market offered little support. U.S. stocks edged lower in a subdued, light-volume session ahead of the Fed minutes, which investors will scan for clues on the 2026 rate path. “It’s been a year of corporate resilience,” Ross Mayfield, an investment strategy analyst at Baird, said. Reuters

For Rivian, investors remain focused on cash burn — how quickly the company spends its cash — and whether higher production efficiency and software revenue can narrow losses as competition keeps pricing tight.

The next company-specific checkpoint is Rivian’s quarterly production and delivery update, which it has historically released shortly after the quarter ends. Rivian last year published its fourth-quarter production and delivery figures in early January and paired that update with timing for its results call. Rivian

In the near term, traders will watch whether the shares stabilize around $19, near Tuesday’s session low, after the stock slipped below the $21 level cited in the CEO’s disclosed sale.

Stock Market Today

  • Two under-$10 stocks that could double in 2026: Opendoor Technologies and Sweetgreen
    December 30, 2025, 5:25 PM EST. Two under-$10 names could double in 2026: Opendoor Technologies and Sweetgreen. Through late December, Opendoor was up about 260% in 2025 after a management reshuffle and a turnaround plan aimed at break-even on adjusted net income by year-end 2026. With mortgage rates around 6% and signs housing demand could recover, the stock's upside hinges on macro strength and execution. Sweetgreen faces a tougher year, but easier year-over-year comparisons and potential improvements in same-store sales could spark a rebound if the broader economy cooperates. The prospect of a double is speculative and relies on favorable macro conditions; as of Dec. 29, 14 S&P 500 components had doubled this year.
XRP price today: Ripple token steadies near $1.88 as Fed minutes loom
Previous Story

XRP price today: Ripple token steadies near $1.88 as Fed minutes loom

ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade
Next Story

ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade

Go toTop